Andrea Bertotti
Overview
Explore the profile of Andrea Bertotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
6340
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Viviani M, Montemurro M, Trusolino L, Bertotti A, Urgese G, Grassi E
Front Bioinform
. 2023 Apr;
3:1143014.
PMID: 37063647
Making raw data available to the research community is one of the pillars of Findability, Accessibility, Interoperability, and Reuse (FAIR) research. However, the submission of raw data to public databases...
12.
Candiello E, Reato G, Verginelli F, Gambardella G, D Ambrosio A, Calandra N, et al.
Mol Oncol
. 2023 Mar;
17(7):1280-1301.
PMID: 36862005
In colorectal cancer, the mechanisms underlying tumor aggressiveness require further elucidation. Taking advantage of a large panel of human metastatic colorectal cancer xenografts and matched stem-like cell cultures (m-colospheres), here...
13.
Falcinelli M, DellOmo G, Grassi E, Mariella E, Leto S, Scardellato S, et al.
Cell Death Dis
. 2023 Feb;
14(2):96.
PMID: 36759506
Telomere maintenance is necessary to maintain cancer cell unlimited viability. However, the mechanisms maintaining telomere length in colorectal cancer (CRC) have not been extensively investigated. Telomere maintenance mechanisms (TMM) include...
14.
Leto S, Ferri M, Sassi F, Zanella E, Cottino F, Vurchio V, et al.
Clin Cancer Res
. 2023 Jan;
29(6):1102-1113.
PMID: 36622698
Purpose: Approximately 20% of patients with RAS wild-type metastatic colorectal cancer (mCRC) experience objective responses to the anti-EGFR antibody cetuximab, but disease eradication is seldom achieved. The extent of tumor...
15.
Russo M, Pompei S, Sogari A, Corigliano M, Crisafulli G, Puliafito A, et al.
Nat Genet
. 2022 Jul;
54(7):976-984.
PMID: 35817983
Compelling evidence shows that cancer persister cells represent a major limit to the long-term efficacy of targeted therapies. However, the phenotype and population dynamics of cancer persister cells remain unclear....
16.
Jaaks P, Coker E, Vis D, Edwards O, Carpenter E, Leto S, et al.
Nature
. 2022 Feb;
603(7899):166-173.
PMID: 35197630
Combinations of anti-cancer drugs can overcome resistance and provide new treatments. The number of possible drug combinations vastly exceeds what could be tested clinically. Efforts to systematically identify active combinations...
17.
Dudova Z, Conte N, Mason J, Stuchlik D, Pesa R, Halmagyi C, et al.
BMC Genomics
. 2022 Feb;
23(1):156.
PMID: 35193494
Background: Patient-derived xenografts (PDX) mice models play an important role in preclinical trials and personalized medicine. Sharing data on the models is highly valuable for numerous reasons - ethical, economical,...
18.
Tedesco M, Giannese F, Lazarevic D, Giansanti V, Rosano D, Monzani S, et al.
Nat Biotechnol
. 2021 Oct;
40(2):235-244.
PMID: 34635836
Recent efforts have succeeded in surveying open chromatin at the single-cell level, but high-throughput, single-cell assessment of heterochromatin and its underlying genomic determinants remains challenging. We engineered a hybrid transposase...
19.
Lafferty A, OFarrell A, Migliardi G, Khemka N, Lindner A, Sassi F, et al.
Clin Cancer Res
. 2021 Aug;
27(21):5979-5992.
PMID: 34426441
Purpose: Regorafenib (REG) is approved for the treatment of metastatic colorectal cancer, but has modest survival benefit and associated toxicities. Robust predictive/early response biomarkers to aid patient stratification are outstanding....
20.
Invrea F, Punzi S, Petti C, Minelli R, Peoples M, Bristow C, et al.
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359705
Colorectal cancer (CRC) is a heterogeneous disease showing significant variability in clinical aggressiveness. Primary and acquired resistance limits the efficacy of available treatments, and identification of effective drug combinations is...